Table 3 Baseline clinical and pathological characteristics of validation cohort B
Clinical variable | No response | Response | OR (95% CI)a | |
|---|---|---|---|---|
N (%) | 25 (42.4) | 34 (57.6) | – | |
Age (year) | 49.7 ± 17.4 | 59.9 ± 14.7 | 0.96 (0.93–0.995)* | |
Gender (male %) | 19 (76.0) | 20 (58.8) | 0.45 (0.14–1.42) | |
MAP (mmHg) | 103.8 ± 14.0 | 101.8 ± 12.4 | 1.01 (0.97–1.05) | |
BMI (kg/m2) | 25.6 ± 3.0 | 24.7 ± 3.2 | 1.11 (0.93–1.32) | |
Ln(Pro) (g/24 h) | 2.0 ± 0.4 | 1.8 ± 0.4 | 2.76 (0.75–10.16) | |
Albumin (g/L) | 19.0 ± 4.7 | 18.3 ± 4.1 | 1.04 (0.92–1.17) | |
eGFR (mL/min/1.73 m2) | 91.1 ± 24.6 | 87.3 ± 28.1 | 1.01 (0.99–1.03) | |
TG (mmol/L) | 2.8 ± 1.3 | 3.5 ± 3.6 | 0.91 (0.72–1.14) | |
TC (mmol/L) | 7.9 ± 2.9 | 8.0 ± 1.4 | 0.96 (0.75–1.23) | |
Ln(β2-MG/uCr) (ug/mmol) | 3.8 ± 2.2 | 3.4 ± 1.5 | 1.15 (0.84–1.57) |
Pathological evaluation | Score | No response | Response | OR (95% CI) |
|---|---|---|---|---|
MN (%) | 25 | 34 | ||
Global sclerosis (%) | 0 | 13 (52.0) | 9 (26.5) | -ref- |
1 | 12 (48.0) | 25 (73.5) | 0.33 (0.11–0.99) | |
Segmental sclerosis (%) | 0 | 23 (92.0) | 31 (91.2) | -ref- |
1 | 2 (8.0) | 3 (8.8) | 0.90 (0.14–5.82) | |
Interstitial fibrosis (%) | 0 | 3 (12.0) | 3 (8.8) | -ref- |
1 | 22 (88.0) | 31 (91.2) | 0.71 (0.13–3.85) | |
Inflammatory cell infiltration (%) | 0 | 1 (4.0) | 4 (11.8) | -ref- |
1 | 24 (96.0) | 30 (88.2) | 3.20 (0.33–30.55) | |
Tubular atrophy (%) | 0 | 3 (12.0) | 4 (11.8) | -ref- |
1 | 22 (88.0) | 30 (88.2) | 0.98(0.20–4.82) | |
Vascular lesion (%) | 0 | 10 (40.0) | 7 (20.6) | -ref- |
1 | 15 (60.0) | 27 (79.4) | 0.39 (0.12–1.23) |